Cannabis Hyperemesis Syndrome

Cannabis Hyperemesis Syndrome in Type 1 Diabetes (ADA 2025 Standards)

This CDS tool aids in the detection of Cannabis Hyperemesis Syndrome (CHS) in individuals with Type 1 Diabetes Mellitus (T1DM) experiencing diabetic ketoacidosis (DKA) with ketosis but lacking significant metabolic acidosis. It evaluates clinical and laboratory parameters to support differential diagnosis and guide management decisions.

Type 1 Diabetes Mellitus (T1DM) Hyperglycemia (Blood Glucose ≥250 mg/dL) Ketosis (β-Hydroxybutyrate >0.6 mmol/L) pH ≥7.4 and Bicarbonate >15 mmol/L (Minimal or No Metabolic Acidosis) Clinical Symptoms: Severe Nausea, Abdominal Pain, Vomiting Recent Cannabis Use

Diagnosis of CHS in patients with T1DM

CHS={ True, if ​ (Glucose≥250)∧(Anion Gap>10)∧(β-Hydroxybutyrate>0.6)∧(pH≥7.4)∧(Bicarbonate>15)∧(Nausea, Vomiting, Pain)∧(Cannabis Use)∧(Type 1 Diabetes)
False, if Any of the above criteria are not met ​

 

American Diabetes Association (ADA) 2025 Standards of Care, Section on Diabetes Ketoacidosis and Cannabis Hyperemesis Syndrome

Börm Bruckmeier Verlag GmbH

1.0

2024/03/04

849